Alfresa Pharma Corporation
https://www.alfresa-pharma.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alfresa Pharma Corporation
Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs
Japan will raise reimbursement prices for selected essential and clinically valuable drugs in April, while cutting back prices for a higher than usual number of other products through the broad application of market expansion repricing rules. The overall regular revision will see prices cut by 4.7% on average.
Nordics BioPharma Sector In Rude Health Despite Global Downturn
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.
Finance Watch: Public Markets Open Back Up For Biopharma Offerings
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Orion Exits Neuro To Concentrate On Cancer And Pain
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Medical Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Alfresa Holdings Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice